| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 929.0 | 965.0 | 738.0 |
| Other income | 31.0 | 45.0 | 20.0 |
| Total income | 960.0 | 1010.0 | 758.0 |
| Profit before exceptional items & tax | 116.0 | 167.0 | -12.0 |
| Exceptional items | 0.0 | 22.0 | -97.0 |
| Profit before tax | 116.0 | 189.0 | -109.0 |
| Net profit | 107.0 | 164.0 | -108.0 |
| Operating margin | 12.1% | 18.7% | -14.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | -34.80% |
|---|---|
| Revenue, year on year | +25.90% |
| Operating profit, year on year | +365.60% |
| Operating profit, quarter on quarter | -30.30% |
BSE results filing, NSE: WOCKPHARMA. Figures extracted from the filing.
Wockhardt Ltd: key numbers
- Share price
- ₹2,265.60
- Market cap
- ₹36,814 Cr
- Revenue (annual)
- ₹3,373 Cr
- Net profit (annual)
- ₹213.0 Cr
- P/E (TTM)
- 90.0×Sector 50.4×
- Promoter holding
- 49.08%+0.00% QoQ
- FII holding
- 7.23%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Wockhardt Ltd
All →Wockhardt Earnings Call: Key Takeaways
Wockhardt reports FY26 revenue of ₹3,373cr with 51% EBITDA growth. Strategy focuses on novel antibiotic 'Zaynich', recently US FDA approved, and diabetes biosimilars to drive future scaling.
Wockhardt Earnings Call: Key Takeaways
Wockhardt FY26 revenue reached INR 3,373 Cr with EBITDA of INR 630 Cr (18.6% margin). Strategy focuses on Novel Antibiotics (Zaynich) and Biosimilars.
Wockhardt Q4 FY26 Results: Turns Profitable, Net Profit ₹164 Cr
Wockhardt Ltd reported revenue from operations of ₹965 Cr (+29.9% YoY) and net profit of ₹164 Cr for Q4 FY26.
- Key figure
- Net profit ₹164 Cr